Key Takeaways:
GE HealthCare Technologies Inc. (Nasdaq: GEHC) saw its shares slide after reporting first-quarter adjusted earnings of $0.99 per share that missed estimates and lowering its full-year profit outlook.
"Profitability in the first quarter was impacted by a PDx supplier issue that has since been resolved," GE HealthCare President and CEO Peter Arduini said in a statement. "Given these dynamics, we are taking a prudent approach and reducing our profit outlook but expect to offset more than half of the inflation impact with price and cost actions."
The medical technology firm posted revenue of $5.1 billion, a 7.4 percent year-over-year increase that beat analyst expectations, driven by strong performance in its Pharmaceutical Diagnostics (PDx) and Imaging segments. However, the company's adjusted EBIT margin fell 150 basis points to 13.5 percent.
The company's performance was mixed across its segments. The Pharmaceutical Diagnostics unit was a bright spot, with revenues surging 21.7 percent to $770 million. Imaging revenue grew 7.4 percent to $2.3 billion. Conversely, the Patient Care Solutions segment saw an 6.5 percent decline in revenue to $704 million.
Looking ahead, GE HealthCare reduced its full-year 2026 guidance. It now expects adjusted earnings per share in the range of $4.80 to $5.00, down from the previous range of $4.95 to $5.15. The company also trimmed its adjusted EBIT margin forecast to a range of 15.4 percent to 15.7 percent. The outlook for organic revenue growth remains unchanged at 3.0 percent to 4.0 percent.
The lowered guidance reflects pressures from increased costs for memory chips, oil, and freight, which the company expects to persist through 2026. The results and guidance position GE HealthCare against competitors like Siemens Healthineers AG and Koninklijke Philips N.V. in a challenging macroeconomic environment.
The guidance cut suggests management anticipates continued margin pressure despite strong demand. Investors will be closely watching the company's second-quarter results for signs of margin stabilization and the effectiveness of its cost-cutting measures.
This article is for informational purposes only and does not constitute investment advice.
